Comparative evaluation of aqueous solution and oil emulsion formulations of 0.05% cyclosporine eye drops in dry eye disease - A randomized clinical trial

被引:0
作者
Salam, Ayesha A. [1 ]
Sen, Seema [2 ]
Lomi, Neiwete [1 ]
Gupta, Noopur [1 ]
Vanathi, Murugesan [1 ]
Tandon, Radhika [1 ]
机构
[1] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ophthalmol, New Delhi, India
[2] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Pathol, New Delhi, India
关键词
Aqueous solution; cyclosporine eyedrops; dry eye disease; impression cytology; oil emulsion; tear meniscus height; OPHTHALMIC EMULSION; EFFICACY; MODERATE; SAFETY;
D O I
10.4103/IJO.IJO_1850_24
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose:To compare the clinical response of patients with moderate-to-severe dry eye disease to treatment with 0.05% cyclosporine eye drops as an aqueous solution or oil emulsion. Study Design:Prospective randomized clinical trial. Methods:An institutional study where 88 patients with moderate-to-severe dry eye was enrolled after written informed consent and randomized to receive either aqueous solution (Group 1) or oil emulsion (Group 2) 0.05% cyclosporine eye drops in twice daily dosing in addition to lubricant eyedrop 0.5% carboxymethylcellulose six times/day in both eyes. Comprehensive eye examination and baseline parameters were recorded, and clinical assessment was repeated at 4, 8, and 12 weeks. Parameters evaluated included ocular surface disease index score (OSDI), Schirmer test, tear break-up time (TBUT), corneal fluorescein staining - National Eye Institute (NEI) scoring, lipid layer thickness (LLT), tear meniscus height (TMH), non-invasive tear break-up time (NIBUT), percentage loss of meibomian glands, and impression cytology (number of goblet cells/hpf). Results:The mean age was 39 +/- 15.6 years and 42 +/- 17.7 years, and the M:F ratio was 26:19 and 20:24 in Groups 1 and 2, respectively. Both the groups showed comparable values at baseline. After treatment, there was statistically significant improvement over baseline values in both groups at 4, 8, and 12 weeks. At 12 weeks for the following parameters, there was no significant difference between the groups, though there was an improvement over baseline in Groups 1 and 2, respectively, as follows: OSDI score - 30.89, 33.28 (P < 0.001), Schirmer test - 5 mm, 4 mm (P < 0.001), TBUT - 2.65 sec, 3.07 sec (P < 0.001), NEI score - 2, 2 (P < 0.001) and the number of goblet cells/hpf - 1.5,9 (P = 0016, P = 0.001). A higher number of patients, by a value of 9, in Group 2 showed an increase in the number of goblet cells/hpf. The NIBUT value showed statistically significant improvement in Group 2 compared to Group 1 (P = 0.011). Group 2 also showed statistically significant improvement in TMH by the 8th week (P = 0.015) and in LLT by the 12th week (P < 0.001). Group 1 comparatively showed earlier improvement in LLT by the 4th week (P = 0.027). Conclusion:Both aqueous solution and oil emulsion 0.05% cyclosporine formulations appear to be equally effective in the management of dry eye disease with a comparatively better response with oil emulsion formulations.
引用
收藏
页码:577 / 581
页数:5
相关论文
共 8 条
  • [1] A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome
    Baiza-Duran, Leopoldo
    Medrano-Palafox, Javier
    Hernandez-Quintela, Everardo
    Lozano-Alcazar, Jaime
    Felix Alaniz-de la O, J.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2010, 94 (10) : 1312 - 1315
  • [2] TFOS DEWS II pathophysiology report
    Bron, Anthony J.
    de Paiva, Cintia S.
    Chauhan, Sunil K.
    Bonini, Stefano
    Gabison, Eric E.
    Jain, Sandeep
    Knop, Erich
    Markoulli, Maria
    Ogawa, Yoko
    Perez, Victor
    Uchino, Yuichi
    Yokoi, Norihiko
    Zoukhri, Driss
    Sullivan, David A.
    [J]. OCULAR SURFACE, 2017, 15 (03) : 438 - 510
  • [3] TFOS DEWS II Definition and Classification Report
    Craig, Jennifer P.
    Nichols, Kelly K.
    Akpek, Esen K.
    Caffery, Barbara
    Dua, Harminder S.
    Joo, Choun-Ki
    Liu, Zuguo
    Nelson, J. Daniel
    Nichols, Jason J.
    Tsubota, Kazuo
    Stapleton, Fiona
    [J]. OCULAR SURFACE, 2017, 15 (03) : 276 - 283
  • [4] Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis
    Gao, Dongyang
    Da, Zhuoli
    Yang, Kan
    Shi, Yuanyuan
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts
    Lallemand, Frederic
    Schmitt, Mathieu
    Bourges, Jean-Louis
    Gurny, Robert
    Benita, Simon
    Garrigue, Jean-Sebastien
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2017, 117 : 14 - 28
  • [6] Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease
    Sall, K
    Stevenson, OD
    Mundorf, TK
    Reis, BL
    [J]. OPHTHALMOLOGY, 2000, 107 (04) : 631 - 639
  • [7] TFOS DEWS II Epidemiology Report
    Stapleton, Fiona
    Alves, Monica
    Bunya, Vatinee Y.
    Jalbert, Isabelle
    Lekhanont, Kaevalin
    Malet, Florence
    Na, Kyung-Sun
    Schaumberg, Debra
    Uchino, Miki
    Vehof, Jelle
    Viso, Eloy
    Vitale, Susan
    Jones, Lyndon
    [J]. OCULAR SURFACE, 2017, 15 (03) : 334 - 365
  • [8] Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease -: A dose-ranging, randomized trial
    Stevenson, D
    Tauber, J
    Reis, BL
    [J]. OPHTHALMOLOGY, 2000, 107 (05) : 967 - 974